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Aim: To evaluate the outcome of prostate cancer patients with initial PSA value >40 ng/ml.
Background: The outcome of prostate cancer patients with very high initial PSA value is not
known and patients are frequently treated with palliative intent. We  analyzed the outcome
of  radical combined hormonal treatment and radiotherapy in prostate cancer patients with
initial PSA value >40 ng/ml.
Methods: Between January 2003 and December 2007 we treated, with curative intent, 56
patients with non-metastatic prostate cancer and initial PSA value >40 ng/ml. The treat-
ment  consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical
radiotherapy (68–78 Gy, conformal technique) and an optional two-year adjuvant hormonal
treatment.
Results: The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year
biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiother-
apy  dose did not signiﬁcantly inﬂuence the outcome. Late genitourinal and gastrointestinal
toxicity was acceptable.Conclusion: Radical treatment in combination with hormonal treatment and radiotherapy
can  be recommended for this subgroup of prostate cancer patients with good performance
status and life expectancy.
© 2012 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.
node metastasis and distant bone metastasis increase with
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rising PSA value. The prediction value of nomograms  for dis-
ease extent prediction decreases with increasing PSA value.3
High initial PSA value can occur in the absence of metastatic
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Table 2 – Proportion of treatment modalities.
Neoadjuvant hormonal
treatment
Yes  55 (98%), No 1 (2%)
Adjuvant hormonal
treatment
Yes  37 (66%), No 19 (34%)
Radiotherapy—volume Pelvis 48 (86%), prostate 8 (14%)
Radiotherapy—dose (Gy) Median 74 Gy (68–78 Gy)80  reports of practical oncology a
disease induced, for example, by inﬂammation of the prostate,
but values are usually not very high.4 A more  accurate diagno-
sis is, in such cases, difﬁcult and potentially useful methods
may be natrium-ﬂuorid PET scanning for the detection of bone
metastasis5,6 or a PET scan with 11C-cholin.7,8 These examina-
tions are not standard today, however.
Patients with an extremely high PSA value are often treated
with palliative intent. The main risk of this approach is the
progression of localized disease and side-effects accompa-
nying permanent hormonal blockade. On the other hand, a
radical approach with radical radiotherapy carries the risk
of overtreatment, early progression outside the treatment
volume, and side-effects of radical radiotherapy. The addi-
tion of radiotherapy to the permanent hormonal treatment
increased overall survival of patients with locally advanced
prostate cancer9 and the addition of hormonal therapy to
radiotherapy increased overall survival of high risk prostate
patients.10,11 The question remains, if the radical treatment
approach is also suitable for patients with extremely high ini-
tial PSA value.
Aim
The aim of this work is to evaluate treatment results in a group
of prostate cancer patients with initial PSA value >40 ng/ml.
Materials  and  methods
Between January 2003 and December 2007 we treated, with
curative intent, 56 patients with non-metastatic prostate can-
cer and an initial PSA value >40 ng/ml. Staging investigations
included PSA, biopsy, CT or MRI  scan of pelvis, and bone
scan. The main characteristics of the patient group are out-
lined in Table 1. The treatment consisted of neoadjuvant
hormonal treatment (2 months, LHRH analog), radiotherapy
and optional adjuvant hormonal treatment (antiandrogen 2
years). The main characteristics of the treatment are outlined
in Table 2. The treatment was performed on linear acceler-
ators with a nominal photon beam energy of 6 MeV, using a
conformal 3D technique. Clinical target volume for the initial
phase of treatment included the pelvic region with boost to the
prostate/seminal vesicles during the second phase or prostate
Table 1 – Patient characteristics.
Age (years) Median 68 (52–81)
T stage
T1 7 (12.5%)
T2 28 (50%)
T3a 9 (16%)
T3b 7 (12.5%)
T4 4 (7%)
Tx 1 (2%)
N0 56 (100%)
Gleason score 2–6 25 (45%)
Gleason score 7 15  (27%)
Gleason score 8–10 14 (25%)
Gleason score x 2 (3%)
PSA (ng/ml) Median 68 ng/ml (42–276)gland/seminal vesicles only, dependent on the decision of the
physician. The dose was 44–50 Gy/22–25 fractions for the pelvic
region and 24–28 Gy/12–14 fractions for the prostate ± seminal
vesicles. The total dose was 68–78 Gy/7–8 weeks. The dose
was normalized to the maximum in PTV and the dose was
prescribed to the reference isodose (usually 93%). Acute and
late toxicity was evaluated according to the RTOG scale. The
follow-up investigations were performed at 3–6 months inter-
vals with PSA examination, physical examination, and control
CT/MRI of pelvis, and bone scan in the case of PSA elevation.
PSA relapse was assessed according to the Phoenix criteria.
Statistics
Overall survival (OS) and biochemical disease free survival
(bDFS) were calculated using the Kaplan–Meier method. Uni-
variate analysis of predictive factors was undertaken using the
Mantel-Cox test. The log-rank test provided a statistical com-
parison of two groups. A p-value <0.05 was considered to be
signiﬁcant.
Results
The median follow up time during the evaluation period
(March 2011) was 61 months. 52 patients were alive, three
patients died due to tumor progression, and one died without
tumor. 5-Year overall survival was 90% and 5-year biochemical
disease free survival (bDFS) was 62%. Kaplan–Meier survival
curves for overall and biochemical-disease free survival are
shown in Fig. 1. We also analyzed the inﬂuence of T stage,
Gleason score, PSA level (with median cut-off), radiotherapy
target volume (prostate only versus whole pelvis), radio-
therapy dose (with 74 Gy cut-off), and adjuvant hormonal
treatment to the biochemical relapse-free survival. None of
these factors signiﬁcantly inﬂuenced bDFS. There was a strong
trend for better results in the group with PSA values below
the median (67.5 ng/ml, p = 0.075). 20 (37.5%) treatment failures
were observed during the time of evaluation. PSA relapse alone
was detected in 10 (17.8%) patients, eight (14.3%) patients
had PSA relapse followed by bone dissemination, one (1.8%)
patient had PSA relapse, local relapse, and bone dissemination
and one (1.8%) patient had PSA relapse and paraaortal lymph
node dissemination. Acute and late toxicity were evaluated
according to the RTOG scale. Therapy of the rectal bleeding
with Argon-laser was considered as grade III toxicity. The data
for acute and late gastrointestinal (GI) and genitourinal (GU)
toxicity can be found in Table 3. No toxicity ≥ 2 for other organs
was  observed.
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Table 3 – Acute and late GI and GU toxicity.
RTOG scale Gr.0 Gr.1 Gr.2 Gr.3 Gr.4
Acute GI 30% 29% 41% 0% 0%
Acute GU 16% 53.4% 27% 1.8% 1.8%
Late GI 41.1% 19.6% 33.9% 5.4%a 0%
Late GU 87.5% 1.8% 
a Argon-laser coagulation was considered as gr.3 late rectal toxicity.
Fig. 1 – Overall survival (a) and biochemical-disease free
s
D
A
aurvival (bDFS) (b).iscussion
n initial PSA value higher than 40 ng/ml is considered as
 very poor prognostic factor and physicians often offer10.7% 0% 0%
less radical or only palliative treatment for this subgroup
of patients. The value of the PSA which excludes patients
from radical treatment is not known. Some studies used
PSA > 150 ng/ml as an exclusion criterion. The main problem
in the treatment of this subgroup of prostate cancer patients
is the risk of local overtreatment with possible late effects of
radiotherapy in the radical approach. On the other hand, there
is a high risk of progression of localized disease in combina-
tion with side-effects of the whole-life hormonal treatment
in the palliative approach. Treatment should be sufﬁciently
effective in the disease control with an acceptable frequency
of side effects. The main question is how many  patients are
without tumor progression upon the completion of treatment
and if the treatment toxicity is acceptable.
A possible solution is a better selection of patients for
radical treatment. Some proportion of patients had dissem-
inated disease at the time of diagnosis, but a signiﬁcant
proportion of patients with high initial PSA had tumor lim-
ited to the prostate, without extra prostatic extension or
seminal vesicle invasion.12 Current methods often cannot
discriminate disseminated disease. Bone scans with 99Tc is
a standard examination in prostate cancer patients with
PSA > 20 ng/ml. The probability of bone metastasis in this
group is higher than 20% and the risk increases with rising
values.13 Natrium ﬂuoride PET may offer higher sensitivity
but reports about this method are controversial. Markers of
bone metabolism, like bone formation markers (bone spe-
ciﬁc alkaline phosphatase, propeptides of type I collagen),
bone resorption markers (bone sialoprotein), and osteoclas-
togenesis markers (osteoprotegerin) are other possibilities
for improving the detection of bone metastasis.14–16 Dis-
tinct suggestions for diagnosing skeletal lesions for patients
with extremely high PSA levels do not exist. Second most
probable locations of dissemination are pelvic or paraaor-
tal lymph nodes. The standard investigation is a CT scan.
Magnetic resonance imaging does not have a better sen-
sitivity than a CT for detecting lymph node metastasis.17
Metastases to other organs are extremely rare and it is not nec-
essary to deal with them. Cholin-PET is a promising method
with sensitivity of 55–100% and speciﬁcity of 77–86% for the
detection of primary tumors.7,18–20 Sensitivity and speciﬁcity
of 18F-ﬂuorocholin for the detection of lymph-node metas-
tasis in men  with intermediate or high risk tumors were
45% and 96%, respectively.21 Others investigated the value
of this examination in the detection of bone metastasis
and speciﬁed values of sensitivity at 79% and speciﬁcity at
97%.22Our strategy of radical treatment includes neoadjuvant
hormonal treatment, radical radiotherapy (with dose escala-
tion in signiﬁcant proportion of men), and optionally adjuvant
hormonal therapy.
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The effectiveness of neoadjuvant hormonal treatment was
demonstrated in a number of clinical studies. This treat-
ment has a low incidence of side-effects and is indicated for
patients with intermediate and high risk prostate cancer.23,24
We  used a short term hormonal treatment, although today a
longer neoadjuvant treatment is recommended.25 PSA decline
after neoadjuvant treatment may be used as another prog-
nostic factor for the decision between radical and palliative
treatment.26
Radiotherapy is the key factor in determining the success
of radical treatment and the severity of side effects in com-
parison with the palliative approach. The effect of radiation
depends on dose, target volumes, and radiotherapy technique.
The treatment of the pelvic lymphatic region has some advan-
tages in comparison with prostate only radiotherapy in high
risk prostate cancer patients. RTOG 9413 trials demonstrated
a 13% improvement of progression free survival for pelvic
RT versus prostate only RT.27–29 Our data showed a much
better disease free survival for the prostate only radiother-
apy group. The limited volume was indicated only for T1
or T2 stage, Gleason score <7 and PSA below median value
and, therefore, the number of these patients was small (14%).
In spite of this, we  hypothesized that this was a selection
bias and that whole pelvis radiotherapy was indicated in this
extremely high risk group, especially higher T stage or Glea-
son score. Dose-response characteristics of prostate cancer
are well documented.30,31 Effects of higher dosage were not
demonstrated in our group. There is some trend for better
results with higher doses. We hypothesized that this might
be due to the short time of follow up. The next issue is the
frequency of late effects of the radiotherapy. We used a 3D con-
formal technique. IMRT  technique signiﬁcantly reduces the
number of side effects, as was demonstrated,32 and may be
used for additional dose escalation.33,34 The majority of late
effects were in our rectal bleeding group. 5.4% of our patients
needed treatment with laser coagulation and none of them
required surgery. We did not observe urogenital late effects
worse than grade 2. Our conclusion from toxicity data is that
beneﬁts of adding radiotherapy are much higher than disad-
vantages. The frequency of late site effects was similar as
in published reports for the 3D CRT.35 Moreover, we hypoth-
esize, that by using IMRT  and optimization of treatment
position the frequency of side effects may be signiﬁcantly
diminished.36,37
Adjuvant hormonal therapy is a standard option in the
high risk prostate cancer group and improves overall sur-
vival of high risk group by 16%.38 However, long-term adjuvant
treatment has many  side effects, including cardiovascular dis-
orders and a higher incidence of diabetes,39,40 although recent
reports dispute the risk of cardiovascular effects.41 We  did not
observed statistically signiﬁcant difference between adjuvant
treatment and no adjuvant treatment. We indicate AHB espe-
cially in patients with high Gleason score (8–10) or stage T3b
or higher. AHB is optional for other patients. Interestingly, we
did not observe any differences in bDFS between higher and
lower Gleason score groups or higher and lower T stage. We
hypothesize that neoadjuvant hormonal treatment in com-
bination with radical radiotherapy may be sufﬁcient in high
risk patients with a low Gleason score and low T stage. This
assumption needs further evaluation.diotherapy 1 7 ( 2 0 1 2 ) 79–84
Treatment failure, in the majority of patients, consisted of
PSA failure followed by bone metastasis. Only one relapse in
the radiotherapy treatment volume was observed. Very low
frequency of local problems is another beneﬁt of the radi-
cal approach. There was a statistically insigniﬁcant trend for
better results for the subgroup with initial PSA value below
median value of 68 ng/ml, as can be expected. 5-Year bDFS for
this subgroup is 76% and for patients with higher initial values
it is 48%. I can be concluded that, speciﬁcally, patients with PSA
values of 40–70 ng/ml should be treated with a radical intent.
Data about treatment outcome of patients with very high
initial PSA values are not available. Recently, Canadian authors
published bDFS and OS at 5 years 39% and 78%, respectively,
in 64 patients with initial PSA > 40 ng/ml. Our results are bet-
ter, possibly due to higher doses and intensive hormonal
treatment.42
Conclusion
Radical treatment of patients with initial PSA values >40 ng/ml
has an excellent 5-year biochemical disease free survival with
a low risk of side effects from the treatment. Progression of
disease is usually outside the radiotherapy treatment volume
with local problems eliminated. We can recommend the rad-
ical treatment approach for this subgroup of prostate cancer
patients with a good performance status and life expectancy.
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